Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Acquired by Rhumbline Advisers

Rhumbline Advisers boosted its holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI) by 2,309.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 50,270 shares of the biopharmaceutical company’s stock after purchasing an additional 48,184 shares during the quarter. Rhumbline Advisers owned approximately 0.10% of Puma Biotechnology worth $164,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in PBYI. Great Point Partners LLC acquired a new stake in Puma Biotechnology in the fourth quarter worth about $4,734,000. SG Americas Securities LLC purchased a new position in Puma Biotechnology during the 1st quarter worth approximately $57,000. Acadian Asset Management LLC raised its position in Puma Biotechnology by 2.0% during the first quarter. Acadian Asset Management LLC now owns 1,956,513 shares of the biopharmaceutical company’s stock valued at $10,366,000 after buying an additional 39,239 shares during the period. O Shaughnessy Asset Management LLC increased its holdings in shares of Puma Biotechnology by 127.7% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 77,081 shares of the biopharmaceutical company’s stock valued at $409,000 after purchasing an additional 43,229 shares during the period. Finally, EntryPoint Capital LLC purchased a new stake in Puma Biotechnology in the 1st quarter worth approximately $329,000. Institutional investors own 61.29% of the company’s stock.

Puma Biotechnology Stock Performance

NASDAQ PBYI opened at $2.58 on Monday. The company’s 50-day simple moving average is $2.93 and its 200 day simple moving average is $3.82. The company has a quick ratio of 1.23, a current ratio of 1.32 and a debt-to-equity ratio of 0.90. The stock has a market cap of $126.55 million, a P/E ratio of 7.82 and a beta of 1.09. Puma Biotechnology, Inc. has a twelve month low of $2.13 and a twelve month high of $7.73.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.01. Puma Biotechnology had a net margin of 4.01% and a return on equity of 18.36%. The company had revenue of $47.10 million during the quarter, compared to analyst estimates of $43.99 million. During the same quarter last year, the business posted $0.05 earnings per share. As a group, research analysts forecast that Puma Biotechnology, Inc. will post 0.25 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on PBYI. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Puma Biotechnology in a research report on Friday, August 2nd. StockNews.com lowered Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 13th.

Insider Buying and Selling

In other news, Director Michael Patrick Miller sold 23,358 shares of Puma Biotechnology stock in a transaction on Monday, August 12th. The stock was sold at an average price of $3.49, for a total value of $81,519.42. Following the completion of the sale, the director now directly owns 47,000 shares of the company’s stock, valued at approximately $164,030. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Alan H. Auerbach sold 21,920 shares of the company’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $3.70, for a total value of $81,104.00. Following the completion of the sale, the chief executive officer now owns 7,063,515 shares in the company, valued at $26,135,005.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael Patrick Miller sold 23,358 shares of the business’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $3.49, for a total value of $81,519.42. Following the transaction, the director now owns 47,000 shares of the company’s stock, valued at $164,030. The disclosure for this sale can be found here. Insiders sold 82,263 shares of company stock worth $286,469 in the last quarter. Insiders own 23.70% of the company’s stock.

Puma Biotechnology Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.